Breaking News Instant updates and real-time market news.

CERS

Cerus

$7.39

0.02 (0.27%)

, AMRS

Amyris

$8.01

0.05 (0.63%)

09:28
09/25/18
09/25
09:28
09/25/18
09:28

Stephens to hold a bus tour

Diagnostics / Life Science Tools Bay Area Bus Tour travels throughout the San Francisco area on September 25.

CERS

Cerus

$7.39

0.02 (0.27%)

AMRS

Amyris

$8.01

0.05 (0.63%)

CDNA

CareDx

$26.55

0.57 (2.19%)

CDXS

Codexis

$18.45

0.5 (2.79%)

PACB

Pacific Biosciences

$4.85

0.05 (1.04%)

  • 25

    Sep

  • 25

    Sep

  • 01

    Oct

  • 06

    Nov

  • 15

    Nov

  • 27

    Nov

CERS Cerus
$7.39

0.02 (0.27%)

07/20/18
CANT
07/20/18
NO CHANGE
Target $9
CANT
Overweight
Cerus price target raised to $9 from $7 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Cerus to $9 and reiterates an Overweight rating on the shares after hosting investor meetings with management. The analyst is now more confident that the company's recent momentum should continue. He believes Cerus has "various growth drivers for the next several years". The FDA is moving closer to providing final guidance for methods to reduce bacterial contamination in transfused platelets, and Cerus' pathogen-inactivation technology should be included, Bijou tells investors in a research note.
01/04/18
CANT
01/04/18
INITIATION
Target $5
CANT
Overweight
Cerus assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Cerus with an Overweight rating and $5 price target.
AMRS Amyris
$8.01

0.05 (0.63%)

03/20/18
RILY
03/20/18
NO CHANGE
Target $10
RILY
Buy
Amyris price target raised to $10 from $8 at B. Riley FBR
B. Riley FBR analyst Carter Driscoll raised his price target for Amyris to $10 and added the shares to his firm's Alpha Generator list. The analyst expects the commercial sweetener market to drive a back-half loaded year and positive earnings in 2019. Further, self-funding 2018 operations should quiet liquidity concerns, Driscoll tells investors in a research note. He keeps a Buy rating on Amyris.
01/25/18
01/25/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with an Overweight at Barclays. 2. Amyris (AMRS) initiated with a Buy at B. Riley FBR. 3. Eagle Bulk Shipping (EGLE) initiated with a Buy at Deutsche Bank. 4. Flex Pharma (FLKS) initiated with a Buy at Ladenburg. 5. CME Group (CME) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/30/18
HCWC
08/30/18
NO CHANGE
Target $15
HCWC
Buy
GRAS designation puts Amyris sweetener closer to launch, says H.C. Wainwright
After Amyris announced that its zero-calorie sweetener made from sugarcane received "Generally Recognized as Safe" designation from an independent panel, H.C. Wainwright analyst Amit Dayal said he believes this GRAS designation puts the product another step closer to a full commercial launch. The analyst, who sees the sweetener commercialization as a very important catalyst for Amyris, keeps a Buy rating and $15 price target on the stock.
06/26/18
HCWC
06/26/18
NO CHANGE
HCWC
Amyris partnership with BGI a positive, says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal affirmed a Buy rating and $15 price target on Amyris, saying he believes the joint venture with Chinese genomics company BGI will further expand Amyris's international reach and will help Amyris enter into the multi-billion dollar Chinese medicine market.
CDNA CareDx
$26.55

0.57 (2.19%)

09/05/18
PIPR
09/05/18
NO CHANGE
Target $42
PIPR
Overweight
CareDx price target raised to $42 from $18 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for CareDx to $42 after introducing a model for 2022. The model includes the analyst's previously communicated scenario analysis that reflects $307M in AlloSure revenue as well as incremental contributions from outside the U.S. AlloSure, AlloMap and human leukocyte antigen testing. He continues to recommend new positions in CareDx shares, and the stock remains his top small cap idea.
06/22/18
CHLM
06/22/18
NO CHANGE
CHLM
Buy
Natera's news could be 'headline negative' for CareDx, says Craig-Hallum
Craig-Hallum analyst Alex Nowak reiterated a Buy rating on Natera (NTRA) after the company announced a new non-invasive kidney transplant rejection test. Natera will hold an investor call next Wednesday to discuss its plan in the transplantation and oncology markets, and Nowak thinks a distribution partnership could emerge on the call. Natera's news could be "headline negative" for competitors like CareDx (CDNA), Nowak says.
07/05/18
PIPR
07/05/18
NO CHANGE
Target $21
PIPR
Overweight
Natera price target raised to $21 from $18 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Natera to $21 after Dr. Sarwal presented on the company's dd-cfDNA test for monitoring kidney health at the TTS meeting in Madrid. Dr. Sarwal reiterated the data released last week and noted that Natera's assay can be used logituditally, like AlloSure, which is expected, Quirk tells investors in a research note. Disappointingly, Dr. Sarwal was not certain what the AUC for creatinine was in the broader cohort, the analyst adds. He continues to believe Natera has "material opportunity" in transplant, but that CareDx (CDNA) has a "significant head start in a concentrated market." Quirk keeps an Overweight rating on Natera.
09/18/18
HCWC
09/18/18
NO CHANGE
Target $22
HCWC
Neutral
CareDx price target raised to $22 from $17 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for CareDx to $22 after the company announced that it had launched the Surveillance HeartCare Outcomes Registry at the Annual Scientific Meeting of the Heart Failure Society of America. The analyst believes the "comprehensive" view of HeartCare could further drive the adoption of AlloMap and AlloSure tests. He reiterates a Neutral rating on CareDx.
CDXS Codexis
$18.45

0.5 (2.79%)

03/09/18
JEFF
03/09/18
NO CHANGE
Target $11
JEFF
Buy
Codexis remains a top small-cap growth idea at Jefferies
Jefferies analyst Brandon Couillard says Codexis is entering 2018 with diversifying revenue streams and positive momentum on multiple fronts. The company's guide for over 20% growth does not factor another CodeEvolver deal, which consensus did include, Couillard tells investors in a research note. He thinks the market continues to underappreciate the company's therapeutic discovery opportunity and keeps a Buy rating on the shares with an $11 price target.
09/05/18
CHLM
09/05/18
NO CHANGE
Target $20
CHLM
Buy
Codexis price target raised to $20 from $15 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt raised his price target for Codexis to $20 from $15, while reiterating a Buy rating on the shares. Setting aside the continued success, increasing penetration, expanding applications, and back-end economic potential the company is experiencing within its core Performance Enzymes segment, the analyst believes that CodeEvolver's biotherapeutic applications provide investors with unique upside that is not reflected in the stock price.
06/19/18
COWN
06/19/18
INITIATION
Target $18
COWN
Outperform
Codexis initiated with an Outperform at Cowen
Cowen analyst Doug Schenkel initiated Codexis with an Outperform and $18 price target.
05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.
PACB Pacific Biosciences
$4.85

0.05 (1.04%)

07/18/18
PIPR
07/18/18
NO CHANGE
Target $3.25
PIPR
Neutral
Pacific Biosciences Q2 shaping up as good quarter, says Piper Jaffray
Piper Jaffray analyst William Quirk says his channel checks found 15 Sequels placed in Q2, suggesting Pacific Biosciences had a sequential increase in placements, consistent with management's comments on the Q1 call and slightly ahead of his expectations. The company's Q2 appears to be shaping up as a good quarter ahead of its 2019 introduction of the 8M feature chip, Quirk tells investors in a research note. The analyst is "encouraged" with Pacific's progress, but keeps a Neutral rating on the shares with a $3.25 price target citing the "complex competitive dynamics."
08/09/18
08/09/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Pacific Biosciences (PACB) initiated with an Overweight at Cantor Fitzgerald by analyst Jordan Abrams, who thinks Pacific's long-read next generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. 2. Heico (HEI) initiated with a Neutral at Baird. 3. Zynga (ZNGA) initiated with an Underweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/09/18
CANT
08/09/18
INITIATION
Target $5
CANT
Overweight
Cantor starts Pacific Biosciences with Overweight rating, $5 target
Cantor Fitzgerald analyst Jordan Abrams last night initiated coverage of Pacific Biosciences of California with an Overweight rating and $5 price target. The analyst thinks Pacific's long-read next generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. While the company has seen mixed revenue performance over the past three years, it is "getting close to an inflection point," which the Street is missing, Abrams told investors in a research note. He sees "multiple paths to revenue acceleration."
08/08/18
CANT
08/08/18
INITIATION
Target $5
CANT
Overweight
Pacific Biosciences initiated with an Overweight at Cantor Fitzgerald
Cantor analyst Jordan Abrams initiated Pacific Biosciences with an Overweight and $5 price target.

TODAY'S FREE FLY STORIES

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.